Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension.
Anemia
Hypochromic erythrocytes
Iron deficiency
Pulmonary arterial hypertension
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
09 Nov 2021
09 Nov 2021
Historique:
received:
30
08
2021
accepted:
02
11
2021
entrez:
10
11
2021
pubmed:
11
11
2021
medline:
15
3
2022
Statut:
epublish
Résumé
Iron deficiency affects up to 50% of patients with pulmonary arterial hypertension (PAH) but iron markers such as ferritin and serum iron are confounded by several non-disease related factors like acute inflammation and diet. The aim of this study was to identify a new marker for iron deficiency and clinical outcome in PAH patients. In this single-center, retrospective study we assessed indicators of iron status and clinical parameters specifying the time to clinical worsening (TTCW) and survival in PAH patients at time of initial diagnosis and at 1-year follow-up using univariable and multivariable analysis. In total, 150 patients were included with an invasively confirmed PAH and complete data on iron metabolism. The proportion of hypochromic erythrocytes > 2% at initial diagnosis was identified as an independent predictor for a shorter TTCW (p = 0.0001) and worse survival (p = 0.002) at initial diagnosis as well as worse survival (p = 0.016) at 1-year follow-up. Only a subset of these patients (64%) suffered from iron deficiency. Low ferritin or low serum iron neither correlated with TTCW nor survival. Severe hemoglobin deficiency at baseline was significantly associated with a shorter TTCW (p = 0.001). The presence of hypochromic erythrocytes > 2% was a strong and independent predictor of mortality and shorter TTCW in this cohort of PAH patients. Thus, it can serve as a valuable indicator of iron homeostasis and prognosis even in patients without iron deficiency or anemia. Further studies are needed to confirm the results and to investigate therapeutic implications.
Sections du résumé
BACKGROUND
BACKGROUND
Iron deficiency affects up to 50% of patients with pulmonary arterial hypertension (PAH) but iron markers such as ferritin and serum iron are confounded by several non-disease related factors like acute inflammation and diet. The aim of this study was to identify a new marker for iron deficiency and clinical outcome in PAH patients.
METHODS
METHODS
In this single-center, retrospective study we assessed indicators of iron status and clinical parameters specifying the time to clinical worsening (TTCW) and survival in PAH patients at time of initial diagnosis and at 1-year follow-up using univariable and multivariable analysis.
RESULTS
RESULTS
In total, 150 patients were included with an invasively confirmed PAH and complete data on iron metabolism. The proportion of hypochromic erythrocytes > 2% at initial diagnosis was identified as an independent predictor for a shorter TTCW (p = 0.0001) and worse survival (p = 0.002) at initial diagnosis as well as worse survival (p = 0.016) at 1-year follow-up. Only a subset of these patients (64%) suffered from iron deficiency. Low ferritin or low serum iron neither correlated with TTCW nor survival. Severe hemoglobin deficiency at baseline was significantly associated with a shorter TTCW (p = 0.001).
CONCLUSIONS
CONCLUSIONS
The presence of hypochromic erythrocytes > 2% was a strong and independent predictor of mortality and shorter TTCW in this cohort of PAH patients. Thus, it can serve as a valuable indicator of iron homeostasis and prognosis even in patients without iron deficiency or anemia. Further studies are needed to confirm the results and to investigate therapeutic implications.
Identifiants
pubmed: 34753505
doi: 10.1186/s12931-021-01884-9
pii: 10.1186/s12931-021-01884-9
pmc: PMC8579551
doi:
Substances chimiques
Biomarkers
0
Hemoglobins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
288Informations de copyright
© 2021. The Author(s).
Références
Nephrol Dial Transplant. 2012 Mar;27(3):1076-83
pubmed: 21799206
Clin Chem Lab Med. 2011 Dec 17;50(4):685-7
pubmed: 22505531
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Cell. 2017 Jan 26;168(3):344-361
pubmed: 28129536
Am J Transplant. 2004 Dec;4(12):2075-81
pubmed: 15575912
Cells. 2021 Feb 23;10(2):
pubmed: 33672218
Eur Respir J. 2015 Oct;46(4):903-75
pubmed: 26318161
Gut. 2011 Oct;60(10):1309-16
pubmed: 21561874
Eur Respir J. 2011 Jun;37(6):1386-91
pubmed: 20884742
Am J Clin Pathol. 2002 May;117(5):802-8
pubmed: 12090432
J Rheumatol. 1997 Apr;24(4):804-5
pubmed: 9101524
Int J Cardiol. 2018 Dec 1;272S:4-10
pubmed: 30314839
Pulm Circ. 2015 Sep;5(3):466-72
pubmed: 26401247
ESC Heart Fail. 2020 Oct;7(5):2007-2011
pubmed: 32602663
Eur Respir J. 2020 Nov 12;56(5):
pubmed: 32444411
Thorax. 2011 Apr;66(4):326-32
pubmed: 21297151
Heart. 2011 Jul;97(13):1054-60
pubmed: 21558476
Int J Cardiol. 2014 Aug 1;175(2):233-9
pubmed: 24880481
Int J Lab Hematol. 2016 Aug;38(4):360-5
pubmed: 27160837
PLoS One. 2018 Aug 30;13(8):e0203396
pubmed: 30161261
Br J Haematol. 2013 Jun;161(5):639-48
pubmed: 23573815
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545971
Eur Heart J. 2020 Jul 21;41(28):2681-2695
pubmed: 30903157
Intern Emerg Med. 2020 Jun;15(4):573-585
pubmed: 32040829
J Am Coll Cardiol. 2011 Jul 12;58(3):300-9
pubmed: 21737024
J Heart Lung Transplant. 2019 Dec;38(12):1286-1295
pubmed: 31648845
BMJ. 1992 Jan 25;304(6821):225-6
pubmed: 1739797